TABLE 3.
Association of caffeine consumption with CSF biomarkers at baseline.
| CSF biomarkers | N |
Low caffeine consumption N = 132 |
N |
High caffeine consumption N = 131 |
Mean difference (95% CI) | p‐value |
|---|---|---|---|---|---|---|
| tau (pg/mL) | 55 | 400 (311 to 627) | 63 | 385 (287 to 622) | 0.14 (−0.06 to 0.35) | 0.17 |
| p‐tau181 (pg/mL) | 56 | 62 (49 to 84) | 64 | 60 (47 to 80) | 0.13 (−0.03 to 0.30) | 0.11 |
| Aβ42 (pg/mL) | 50 | 577 (411 to 953) | 57 | 658 (431 to 956) | −0.21 (−0.41 to 0.00) | 0.040 |
| Aβ40 (pg/mL) | 50 | 7075 (5934 to 8647) | 57 | 6795 (5874 to 9007) | −0.05 (−0.18 to 0.09) | 0.47 |
| Aβ42/Aβ40 (%) | 50 | 8.1 (6.7 to 14.0) | 57 | 8.4 (6.8 to 12.9) | −0.17 (−0.32 to −0.01) | 0.047 |
| CSF Aβ42/p‐tau | 49 | 8.5 (5.7 to 17.2) | 54 | 10.5 (6.5 to 21.3) | −0.34 (−0.61 to −0.06) | 0.020 |
Note: Values are presented as median (IQR). Mean differences and p values were calculated on log transformed data and were adjusted for APOE ε4, age, sex, education level, and tobacco consumption, using high caffeine consumption as reference.
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; N, number of available observations.